Xvivo Perfusion AB (publ)

OM:XVIVO Stok Raporu

Piyasa değeri: SEK 15.7b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Xvivo Perfusion Yönetim

Yönetim kriter kontrolleri 3/4

Xvivo Perfusion's CEO'su Christoffer Rosenblad, Jan2022 tarihinde atandı, in görev süresi 2.75 yıldır. şirketin hisselerinin 0.18% doğrudan sahiptir ve bu hisselerin değeri SEK 27.98M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 4 yıldır.

Anahtar bilgiler

Christoffer Rosenblad

İcra Kurulu Başkanı

SEK 5.0m

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi2.8yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi2.3yrs
Yönetim Kurulu ortalama görev süresi4yrs

Son yönetim güncellemeleri

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25
Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11
There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05
Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01
We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28
Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Aug 24
Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Jul 17
Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Jun 16
Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Apr 19
Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

Mar 23
Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

Mar 07
With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Feb 13
When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Dec 14
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20
Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21
Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30
Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18
At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30
A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

CEO

Christoffer Rosenblad (49 yo)

2.8yrs

Görev süresi

SEK 5,031,000

Tazminat

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christoffer Rosenblad
Chief Executive Officer2.8yrsSEK 5.03m0.18%
SEK 27.7m
Kristoffer Nordstrom
Chief Financial Officer3.9yrsVeri yok0.0085%
SEK 1.3m
Lena Hagman
Chief Operating Officer1.8yrsVeri yok0.0063%
SEK 997.1k
Johan Holmstrom
Senior Vice President of Commercial EMEAless than a yearVeri yok0.012%
SEK 1.8m
Ylva Vihoj
Global Human Resources Director1.8yrsVeri yokVeri yok
Magnus Nilsson
Senior Advisor4.3yrsSEK 1.62mVeri yok
Andreas Wallinder
Chief Medical Officer4.1yrsVeri yok0.011%
SEK 1.7m
Mark Reade
Senior Vice President of North Americaless than a yearVeri yokVeri yok

2.3yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: XVIVO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Gosta Johannesson
Chairman of the Board11.8yrsSEK 440.00k0.015%
SEK 2.3m
Lars Henriksson
Independent Director4yrsVeri yok0.0076%
SEK 1.2m
Erik Stromqvist
Independent Director1.5yrsVeri yok0.18%
SEK 27.7m
Camilla Oberg
Independent Director8.4yrsSEK 130.00k0.0034%
SEK 537.0k
Lena Hoglund
Independent Director4yrsVeri yok0.0041%
SEK 648.5k
Goran Dellgren
Independent Director2.5yrsVeri yokVeri yok

4.0yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: XVIVO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).